Therapeutic Use of ApoE-Mimetic Peptides

This publication has 71 references indexed in Scilit:

• Antagonism of nicotinic acetycholinergic receptors by CN‐105, an apoE‐mimetic peptide reduces stroke‐induced excitotoxicity
  Clinical and Translational Medicine, 2022
• HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?
  International Journal of Peptide Research and Therapeutics, 2022
• Apolipoprotein E mimetic peptide, CN‐105, improves outcomes in ischemic stroke
  Annals of Clinical and Translational Neurology, 2017
• Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects
  The Journal of Clinical Pharmacology, 2016
• Inhibition of Blood-Brain Barrier Disruption by an Apolipoprotein E-Mimetic Peptide Ameliorates Early Brain Injury in Experimental Subarachnoid Hemorrhage
  Translational Stroke Research, 2016
• Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders
  Journal of Molecular Medicine, 2016
• Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding
  Hepatology, 2012
• The apoE-mimetic Peptide, COG1410, Improves Functional Recovery in a Murine Model of Intracerebral Hemorrhage
  Neurocritical Care, 2011
• COG1410, a novel apolipoprotein‐E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia
  Journal of Neuroscience Research, 2008
• Apolipoprotein E (ApoE) peptide regulates tau phosphorylation via two different signaling pathways
  Journal of Neuroscience Research, 1998